Overview Study of VIR-2482 in Healthy Volunteers Status: Active, not recruiting Trial end date: 2021-11-01 Target enrollment: Participant gender: Summary This is a phase 1 study in which healthy volunteers will receive VIR-2482 or placebo and will be assessed for safety, pharmacokinetics, and immunogenicity of VIR-2482 in preventing Influenza A illness. Phase: Phase 1 Details Lead Sponsor: Vir Biotechnology, Inc.